Bajaj HealthCare , a prominent player in the pharmaceutical industry, has announced a significant addition to its leadership team. The company's Board of Directors has appointed Mr. Sandeep Shah as an Additional Director in the Non-Executive Non-Independent category, effective August 18, 2025.

Appointment Details

The appointment was approved by the board through a resolution passed by circulation, based on the recommendation of the Nomination & Remuneration Committee. This decision is subject to shareholder approval.

About Sandeep Shah

Mr. Shah brings a wealth of experience to Bajaj Healthcare:

• Commerce graduate
• Over 23 years of experience in Registrar and Share Transfer services
• Worked with organizations including Karvy Consultants Private Limited and Par Computer Sciences (International) Limited
• More than 16 years of experience with a PCS firm handling Company Secretarial work

Compliance and Independence

Mr. Shah has confirmed that he has not been debarred from holding directorship by SEBI or other authorities. He has also declared that he is not related to any existing directors of the company.

Board Composition

The appointment of Mr. Sandeep Shah reflects Bajaj Healthcare's commitment to strengthening its board with diverse expertise. His extensive experience in Registrar and Share Transfer services, as well as Company Secretarial work, is expected to bring valuable insights to the company's governance and operational processes.

Bajaj Healthcare Limited , a leading manufacturer of APIs, Intermediates, and Formulations, has reported impressive financial results for the first quarter, setting the stage for projected strong growth in the coming year.

Financial Highlights

The company's unaudited financial results for the quarter reveal significant improvements across key metrics:

Export API Business Surge

A standout feature of Bajaj Healthcare's performance is the remarkable 68.4% year-on-year growth in its API export business. This surge has been attributed to growing demand in regulated markets and the ramp-up of commercial CDMO (Contract Development and Manufacturing Organization) supplies.

Formulations Growth and Strategic Realignment

The company's formulations segment also showed strong growth, with a 41.1% year-on-year increase. This growth has been driven by deeper market penetration and new strategic partnerships. In response to pricing headwinds in the domestic API segment, Bajaj Healthcare has strategically realigned its portfolio towards value-added exports and differentiated molecules to reinforce growth and profitability.

Regulatory Approvals and CDMO Progress

During the quarter, Bajaj Healthcare received three new CEP approvals and one ASMF approval from European regulatory authorities, strengthening its position in regulated EU/UK markets. The company has also commenced validation batch supplies for several molecules under CDMO agreements. Additionally, five DMFs were filed with the UK MHRA to enable future commercial supply and regulatory compliance.

Pipeline Development and Backward Integration

Bajaj Healthcare continues to evolve its CNS portfolio with notable regulatory developments. Cenobamate has received a positive recommendation from the Subject Expert Committee (SEC) and is awaiting final DCGI approval to initiate Phase III trials. The company is also preparing for the commercial launch of Magtein® in Q3, with validation batches currently underway.

The company's strategy of backward integration remains a cornerstone, especially in supporting scale-up across CDMO and formulation segments. This approach has contributed to the increase in export contribution, which rose to 35% of total revenue in the current quarter, up from 23% in the same quarter last year.

Management Commentary

Mr. Anil Jain, Managing Director of Bajaj Healthcare, commented on the results: "This quarter marks a strong and promising start to the new fiscal year for Bajaj Healthcare, despite a challenging pricing environment in certain segments. We remain firmly on course to build a value-driven, innovation-led growth engine across APIs, formulations, and CDMO."

Future Outlook

With its strong performance and strategic initiatives in place, Bajaj Healthcare is well-positioned for robust growth. The company's focus on expanding its CDMO operations, securing new EU approvals, and advancing its regulatory progress in CNS and nutraceuticals segments is expected to drive future growth and profitability.

As Bajaj Healthcare continues to leverage its strengths in API manufacturing and formulations, while expanding its global footprint, the company appears poised for sustained growth in the coming fiscal year.